Edition:
United Kingdom

ReShape Lifesciences Inc (RSLS.OQ)

RSLS.OQ on NASDAQ Stock Exchange Capital Market

1.61USD
2:40pm GMT
Change (% chg)

$0.03 (+1.90%)
Prev Close
$1.58
Open
$1.58
Day's High
$1.61
Day's Low
$1.58
Volume
3,894
Avg. Vol
122,222
52-wk High
$10.10
52-wk Low
$1.24

Chart for

About

ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC... (more)

Overall

Beta: 3.09
Market Cap(Mil.): $17.00
Shares Outstanding(Mil.): 8.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 149.38 16.62
EPS (TTM): -- -- --
ROI: -- 9.44 10.61
ROE: -- 14.87 14.21

BRIEF-SVLSF IV Reports 14 Pct Passive Stake In Reshape Lifesciences

* SVLSF IV, LLC REPORTS 14 PERCENT PASSIVE STAKE IN RESHAPE LIFESCIENCES AS OF DEC 19 - SEC FILING Source text : (http://bit.ly/2lp7hu7) Further company coverage:

29 Dec 2017

BRIEF-Reshape Lifesciences Inc - ‍Received Order For Reshape Integrated Dual Balloon System From Al Zahrawi ​

* RESHAPE LIFESCIENCES INC - ‍RECEIVED ORDER FOR RESHAPE INTEGRATED DUAL BALLOON SYSTEM FROM AL ZAHRAWI MEDICAL​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

13 Dec 2017

BRIEF-Reshape Lifesciences qtrly loss per share $1.06‍​

* Reshape Lifesciences announces third quarter 2017 financial results

14 Nov 2017

BRIEF-Enteromedics Inc says ‍has formally changed its name to Reshape Lifesciences Inc​

* Enteromedics Inc - ‍has formally changed its name to Reshape Lifesciences Inc​ Source text for Eikon: Further company coverage:

23 Oct 2017

Earnings vs. Estimates